Creatine protects against mitochondrial dysfunction associated with HIV-1 tat-induced neuronal injury

Current HIV Research

Volumn 12, Issue 6, 2014, Pages 378-387

  Stevens, Patrick R ^a   Gawryluk, Jeremy W ^a   Hui, Liang ^a   Chen, Xuesong ^a   Geiger, Jonathan D ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Creatine; HIV 1 associated neurocognitive disorders; HIV 1 Tat; Mitochondria dysfunction; Neuroprotection

Indexed keywords

CREATINE; CREATINE PHOSPHATE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; REACTIVE OXYGEN METABOLITE; NEUROPROTECTIVE AGENT; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOENERGY; BRAIN CELL CULTURE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOBLOTTING; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MTT ASSAY; NERVE INJURY; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; SPECTROPHOTOMETRY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; FEMALE; METABOLISM; MITOCHONDRION; NERVE CELL; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; CELL DEATH; CELLS, CULTURED; CREATINE; FEMALE; HIV-1; METABOLIC NETWORKS AND PATHWAYS; MICE, INBRED C57BL; MITOCHONDRIA; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATION-REDUCTION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84931028282     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162x13666150121101544     Document Type: Article

References (72)

1. [1] Saxena SK, Tiwari S, Nair MP (2012) A global perspective on HIV/AIDS. Science 337, 798.
2. [2] Heaton RK, Clifford DB, Franklin DR, Jr. et al. (2010) HIVassociated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75, 2087-96.
3. [3] Chan P, Brew BJ (2014) HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. Curr HIV/AIDS Rep 11, 317-24.
4. [4] van de Bovenkamp M, Nottet HS, Pereira CF (2002) Interactions of human immunodeficiency virus-1 proteins with neurons: possible role in the development of human immunodeficiency virus-1-associated dementia. Eur J Clin Invest 32, 619-27.
5. [5] Nath A, Geiger J (1998) Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms. Prog Neurobiol 54, 19-33.
6. [6] Haughey NJ, Holden CP, Nath A et al. (1999) Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein tat. J Neurochem 73, 1363-74.
7. [7] Nath A, Haughey NJ, Jones M et al. (2000) Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol 47, 186-94.
8. [8] Buscemi L, Ramonet D, Geiger JD (2007) Human immunodeficiency virus type-1 protein Tat induces tumor necrosis factor-alpha-mediated neurotoxicity. Neurobiol Dis 26, 661-70.
9. [9] Sabatier JM, Vives E, Mabrouk K et al. (1991) Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J Virol 65, 961-7.
10. [10] Weeks BS, Lieberman DM, Johnson B et al. (1995) Neurotoxicity of the human immunodeficiency virus type 1 tat transactivator to PC12 cells requires the Tat amino acid 49-58 basic domain. J Neurosci Res 42, 34-40.
11. [11] Perez A, Probert AW, Wang KK et al. (2001) Evaluation of HIV-1 Tat induced neurotoxicity in rat cortical cell culture. J Neurovirol 7, 1-10.
12. [12] King JE, Eugenin EA, Buckner CM et al. (2006) HIV tat and neurotoxicity. Microbes Infect 8, 1347-57.
13. [13] Agrawal L, Louboutin JP, Reyes BA et al. (2011) HIV-1 Tat neurotoxicity: A model of acute and chronic exposure, and neuroprotection by gene delivery of antioxidant enzymes. Neurobiol Dis.
14. [14] Johnson TP, Patel K, Johnson KR et al. (2013) Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A 110, 13588-93.
15. [15] Haughey NJ, Mattson MP (2002) Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120. J Acquir Immune Defic Syndr 31 Suppl 2, S55-61.
16. [16] Kruman, II, Nath A, Mattson MP (1998) HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp Neurol 154, 276-88.
17. [17] Perry SW, Norman JP, Litzburg A et al. (2005) HIV-1 transactivator of transcription protein induces mitochondrial hyperpolarization and synaptic stress leading to apoptosis. J Immunol 174, 4333-44.
18. [18] Price TO, Ercal N, Nakaoke R et al. (2005) HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells. Brain Res 1045, 57-63.
19. [19] Rappaport J, Joseph J, Croul S et al. (1999) Molecular pathway involved in HIV-1-induced CNS pathology: role of viral regulatory protein, Tat. J Leukoc Biol 65, 458-65.
20. [20] Zou W, Kim BO, Zhou BY et al. (2007) Protection against human immunodeficiency virus type 1 Tat neurotoxicity by Ginkgo biloba extract EGb 761 involving glial fibrillary acidic protein. Am J Pathol 171, 1923-35.
21. [21] Kim HJ, Martemyanov KA, Thayer SA (2008) Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death. J Neurosci 28, 12604-13.
22. [22] Fitting S, Xu R, Bull C et al. (2010) Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 177, 1397-410.
23. [23] Hui L, Chen X, Bhatt D et al. (2012) Ketone bodies protection against HIV-1 Tat-induced neurotoxicity. J Neurochem.
24. [24] Mujika I, Padilla S (1997) Creatine supplementation as an ergogenic aid for sports performance in highly trained athletes: a critical review. Int J Sports Med 18, 491-6.
25. [25] Klivenyi P, Gardian G, Calingasan NY et al. (2003) Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Mol Neurosci 21, 191-8.
26. [26] Seidl SE, Potashkin JA (2011) The promise of neuroprotective agents in Parkinson's disease. Front Neurol 2, 68.
27. [27] Matthews RT, Yang L, Jenkins BG et al. (1998) Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 18, 156-63.
28. [28] Burklen TS, Schlattner U, Homayouni R et al. (2006) The Creatine Kinase/Creatine Connection to Alzheimer's Disease: CKInactivation, APP-CK Complexes and Focal Creatine Deposits. J Biomed Biotechnol 2006, 35936.
29. [29] Rosenfeld J, King RM, Jackson CE et al. (2008) Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph Lateral Scler 9, 266-72.
30. [30] Ma M, Nath A (1997) Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. J Virol 71, 2495-9.
31. [31] Prendergast MA, Rogers DT, Mulholland PJ et al. (2002) Neurotoxic effects of the human immunodeficiency virus type-1 transcription factor Tat require function of a polyamine sensitivesite on the N-methyl-D-aspartate receptor. Brain Res 954, 300-7.
32. [32] Nath A, Psooy K, Martin C et al. (1996) Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J Virol 70, 1475-80.
33. [33] Bough KJ, Wetherington J, Hassel B et al. (2006) Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol 60, 223-35.
34. [34] Hui L, Chen X, Bhatt D et al. (2012) Ketone bodies protection against HIV-1 Tat-induced neurotoxicity. J Neurochem 122, 382-91.
35. [35] Mattson MP, Barger SW, Begley JG et al. (1995) Calcium, free radicals, and excitotoxic neuronal death in primary cell culture. Methods Cell Biol 46, 187-216.
36. [36] Wang X, Mori T, Sumii T et al. (2002) Hemoglobin-induced cytotoxicity in rat cerebral cortical neurons: caspase activation and oxidative stress. Stroke 33, 1882-8.
37. [37] Petronilli V, Miotto G, Canton M et al. (1999) Transient and longlasting openings of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence. Biophys J 76, 725-34.
38. [38] Rama Rao KV, Jayakumar AR, Norenberg MD (2005) Role of oxidative stress in the ammonia-induced mitochondrial permeability transition in cultured astrocytes. Neurochem Int 47, 31-8.
39. [39] Aksenov MY, Aksenova MV, Nath A et al. (2006) Cocainemediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology 27, 217-28.
40. [40] Gavriil ES, Cooney R, Weeks BS (2000) Tat mediates apoptosis in vivo in the rat central nervous system. Biochem Biophys Res Commun 267, 252-6.
41. [41] New DR, Maggirwar SB, Epstein LG et al. (1998) HIV-1 Tat induces neuronal death via tumor necrosis factor-alpha and activation of non-N-methyl-D-aspartate receptors by a NFkappaBindependent mechanism. J Biol Chem 273, 17852-8.
42. [42] Shi B, Raina J, Lorenzo A et al. (1998) Neuronal apoptosis induced by HIV-1 Tat protein and TNF-alpha: potentiation of neurotoxicity mediated by oxidative stress and implications for HIV-1 dementia. J Neurovirol 4, 281-90.
43. [43] Langford D, Grigorian A, Hurford R et al. (2004) The role of mitochondrial alterations in the combined toxic effects of human immunodeficiency virus Tat protein and methamphetamine on calbindin positive-neurons. J Neurovirol 10, 327-37.
44. [44] Raidel SM, Haase C, Jansen NR et al. (2002) Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. Am J Physiol Heart Circ Physiol 282, H1672-1678.
45. [45] Darbinian N, Khalili K, Amini S (2014) Neuroprotective activity of pDING in response to HIV-1 Tat. J Cell Physiol 229, 153-61.
46. [46] Lawler JM, Barnes WS, Wu G et al. (2002) Direct antioxidant properties of creatine. Biochem Biophys Res Commun 290, 47-52.
47. [47] O'Gorman E, Beutner G, Dolder M et al. (1997) The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett 414, 253-7.
48. [48] Sabatier JM, Vives E, Mabrouk K et al. (1991) Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J Virol 65, 961-7.
49. [49] Banks WA, Robinson SM, Nath A (2005) Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol 193, 218-27.
50. [50] Cheng J, Nath A, Knudsen B et al. (1998) Neuronal excitatory properties of human immunodeficiency virus type 1 Tat protein. Neuroscience 82, 97-106.
51. [51] Wallace DR, Dodson SL, Nath A et al. (2006) Delta opioid agonists attenuate TAT(1-72)-induced oxidative stress in SK-N-SH cells. Neurotoxicology 27, 101-7.
52. [52] Singh IN, El-Hage N, Campbell ME et al. (2005) Differential involvement of p38 and JNK MAP kinases in HIV-1 Tat and gp120-induced apoptosis and neurite degeneration in striatal neurons. Neuroscience 135, 781-90.
53. [53] Bonavia R, Bajetto A, Barbero S et al. (2001) HIV-1 Tat causes apoptotic death and calcium homeostasis alterations in rat neurons. Biochem Biophys Res Commun 288, 301-8.
54. [54] Eugenin EA, D'Aversa TG, Lopez L et al. (2003) MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tatinduced apoptosis. J Neurochem 85, 1299-311.
55. [55] Haughey NJ, Nath A, Mattson MP et al. (2001) HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity. J Neurochem 78, 457-67.
56. [56] Self RL, Mulholland PJ, Nath A et al. (2004) The human immunodeficiency virus type-1 transcription factor Tat produces elevations in intracellular Ca2+ that require function of an Nmethyl-D-aspartate receptor polyamine-sensitive site. Brain Res 995, 39-45.
57. [57] Caporello E, Nath A, Slevin J et al. (2006) The immunophilin ligand GPI1046 protects neurons from the lethal effects of the HIV-1 proteins gp120 and Tat by modulating endoplasmic reticulum calcium load. J Neurochem 98, 146-55.
58. [58] Zhu X, Yao H, Peng F et al. (2009) PDGF-mediated protection of SH-SY5Y cells against Tat toxin involves regulation of extracellular glutamate and intracellular calcium. Toxicol Appl Pharmacol 240, 286-91.
59. [59] Wallace DR (2006) HIV neurotoxicity: potential therapeutic interventions. J Biomed Biotechnol 2006, 65741.
60. [60] Dong Z, Saikumar P, Weinberg JM et al. (2006) Calcium in cell injury and death. Annu Rev Pathol 1, 405-34.
61. [61] Zoratti M, Szabo I (1995) The mitochondrial permeability transition. Biochim Biophys Acta 1241, 139-76.
62. [62] Norman JP, Perry SW, Kasischke KA et al. (2007) HIV-1 trans activator of transcription protein elicits mitochondrial hyperpolarization and respiratory deficit, with dysregulation of complex IV and nicotinamide adenine dinucleotide homeostasis in cortical neurons. J Immunol 178, 869-76.
63. [63] Norman JP, Perry SW, Reynolds HM et al. (2008) HIV-1 Tat activates neuronal ryanodine receptors with rapid induction of the unfolded protein response and mitochondrial hyperpolarization. PLoS One 3, e3731.
64. [64] Maragos WF, Young KL, Turchan JT et al. (2002) Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J Neurochem 83, 955-63.
65. [65] Rumbaugh JA, Li G, Rothstein J et al. (2007) Ceftriaxone protects against the neurotoxicity of human immunodeficiency virus proteins. J Neurovirol 13, 168-72.
66. [66] Rumbaugh J, Turchan-Cholewo J, Galey D et al. (2006) Interaction of HIV Tat and matrix metalloproteinase in HIV neuropathogenesis: a new host defense mechanism. FASEB J 20, 1736-8.
67. [67] Ferri KF, Jacotot E, Blanco J et al. (2000) Mitochondrial control of cell death induced by HIV-1-encoded proteins. Ann N Y Acad Sci 926, 149-64.
68. [68] Dolder M, Walzel B, Speer O et al. (2003) Inhibition of the mitochondrial permeability transition by creatine kinase substrates. Requirement for microcompartmentation. J Biol Chem 278, 17760-6.
69. [69] Sullivan PG, Geiger JD, Mattson MP et al. (2000) Dietary supplement creatine protects against traumatic brain injury. Ann Neurol 48, 723-9.
70. [70] Carducci C, Carducci C, Santagata S et al. (2012) In vitro study of uptake and synthesis of creatine and its precursors by cerebellar granule cells and astrocytes suggests some hypotheses on the physiopathology of the inherited disorders of creatine metabolism. Neurosci. 26, 13-41.
71. [71] Chang L, Eernst, T, Witt, MD et al. (2002) Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naive HIV patients. Neuroimage 17, 1638-48.
72. [72] Ernst T, Itti E, Itti L, Chang L (2000) Changes in cerebral metabolism are detected prior to perfusion changes in early HIVCMC: A coregistered (1)H MRS and SPECT study. J. Magn. Reson. Imaging 12, 859-65